17
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Bridging the gap: metabolic and endocrine care of patients during transition

      review-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Objective

          Seamless transition of endocrine patients from the paediatric to adult setting is still suboptimal, especially in patients with complex disorders, i.e., small for gestational age, Turner or Prader–Willi syndromes; Childhood Cancer Survivors, and those with childhood-onset growth hormone deficiency.

          Methods

          An expert panel meeting comprised of European paediatric and adult endocrinologists was convened to explore the current gaps in managing the healthcare of patients with endocrine diseases during transition from paediatric to adult care settings.

          Results

          While a consensus was reached that a team approach is best, discussions revealed that a ‘one size fits all’ model for transition is largely unsuccessful in these patients. They need more tailored care during adolescence to prevent complications like failure to achieve target adult height, reduced bone mineral density, morbid obesity, metabolic perturbations (obesity and body composition), inappropriate/inadequate puberty, compromised fertility, diminished quality of life and failure to adapt to the demands of adult life. Sometimes it is difficult for young people to detach emotionally from their paediatric endocrinologist and/or the abrupt change from an environment of parental responsibility to one of autonomy. Discussions about impending transition and healthcare autonomy should begin in early adolescence and continue throughout young adulthood to ensure seamless continuum of care and optimal treatment outcomes.

          Conclusions

          Even amongst a group of healthcare professionals with a great interest in improving transition services for patients with endocrine diseases, there is still much work to be done to improve the quality of healthcare for transition patients.

          Related collections

          Most cited references27

          • Record: found
          • Abstract: not found
          • Article: not found

          Transition from child-centered to adult health-care systems for adolescents with chronic conditions. A position paper of the Society for Adolescent Medicine.

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II: a statement of the GH Research Society in association with the European Society for Pediatric Endocrinology, Lawson Wilkins Society, European Society of Endocrinology, Japan Endocrine Society, and Endocrine Society of Australia.

            Ken Ho (2007)
            The GH Research Society held a Consensus Workshop in Sydney, Australia, 2007 to incorporate the important advances in the management of GH deficiency (GHD) in adults, which have taken place since the inaugural 1997 Consensus Workshop. Two commissioned review papers, previously published Consensus Statements of the Society and key questions were circulated before the Workshop, which comprised a rigorous structure of review with breakout discussion groups. A writing group transcribed the summary group reports for drafting in a plenary forum on the last day. All participants were sent a polished draft for additional comments and gave signed approval to the final revision. Testing for GHD should be extended from hypothalamic-pituitary disease and cranial irradiation to include traumatic brain injury. Testing may indicate isolated GHD; however, idiopathic isolated GHD occurring de novo in the adult is not a recognized entity. The insulin tolerance test, combined administration of GHRH with arginine or growth hormone-releasing peptide, and glucagon are validated GH stimulation tests in the adult. A low IGF-I is a reliable diagnostic indicator of GHD in the presence of hypopituitarism, but a normal IGF-I does not rule out GHD. GH status should be reevaluated in the transition age for continued treatment to complete somatic development. Interaction of GH with other axes may influence thyroid, glucocorticoid, and sex hormone requirements. Response should be assessed clinically by monitoring biochemistry, body composition, and quality of life. There is no evidence that GH replacement increases the risk of tumor recurrence or de novo malignancy.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              GH safety workshop position paper: a critical appraisal of recombinant human GH therapy in children and adults

              Recombinant human GH (rhGH) has been in use for 30 years, and over that time its safety and efficacy in children and adults has been subject to considerable scrutiny. In 2001, a statement from the GH Research Society (GRS) concluded that ‘for approved indications, GH is safe’; however, the statement highlighted a number of areas for on-going surveillance of long-term safety, including cancer risk, impact on glucose homeostasis, and use of high dose pharmacological rhGH treatment. Over the intervening years, there have been a number of publications addressing the safety of rhGH with regard to mortality, cancer and cardiovascular risk, and the need for long-term surveillance of the increasing number of adults who were treated with rhGH in childhood. Against this backdrop of interest in safety, the European Society of Paediatric Endocrinology (ESPE), the GRS, and the Pediatric Endocrine Society (PES) convened a meeting to reappraise the safety of rhGH. The ouput of the meeting is a concise position statement.
                Bookmark

                Author and article information

                Journal
                Endocr Connect
                Endocr Connect
                EC
                Endocrine Connections
                Bioscientifica Ltd (Bristol )
                2049-3614
                November 2016
                16 November 2016
                : 5
                : 6
                : R44-R54
                Affiliations
                [1 ]Erasmus University Medical Centre Rotterdam, The Netherlands
                [2 ]University Children’s Hospital Essen, Germany
                [3 ]Medical University and General Hospital of Vienna Vienna, Austria
                [4 ]Sahlgrenska University Hospital Göteborg, Sweden
                [5 ]Istituto Giannina Gaslini University of Genova, Genova, Italy
                [6 ]Hospital Infantil Universitario Niño Jesús Madrid, Spain
                [7 ]University Hospital Brussels Brussels, Belgium
                [8 ]Queen Elizabeth Hospital Birmingham, UK
                [9 ]Cardiff University School of Medicine Cardiff, UK
                [10 ]Department of Molecular Medicine and Surgery Karolinska Institute and Department of Endocrinology, Metabolism and Diabetology, Karolinska University Hospital, Stockholm, Sweden
                [11 ]Department of Endocrinology School of Medicine, Erciyes University, Kayseri, Turkey
                [12 ]Department of Pediatrics Klinikum Oldenburg, Medical Campus University Oldenburg, Oldenburg, Germany
                [13 ]Belgrade University School of Medicine Belgrade, Serbia
                [14 ]University of Bologna Bologna, Italy
                [15 ]Department of Women’s and Children’s Health Karolinska Institutet, and Pediatric Endocrinology Unit, Karolinska University Hospital, Stockholm, Sweden
                [16 ]The Christie Hospital Manchester, UK
                [17 ]University of Patras School of Medicine Patras, Greece
                [18 ]Hôpital des Enfants Toulouse, France
                Author notes
                Correspondence should be addressed to A-J van der Lely; Email: a.vanderlelij@ 123456erasmusmc.nl
                [*]

                (Co-Chairs)

                [†]

                (Scientific Planning Committee members)

                [‡]

                (on behalf of Faculty Members)

                Article
                EC160028
                10.1530/EC-16-0028
                5118971
                27803155
                605e4653-a4cf-47e7-899d-42b359b5c15d
                © 2016 The authors

                This work is licensed under a Creative Commons Attribution 4.0 International License.

                History
                : 7 October 2016
                : 1 November 2016
                Product
                Categories
                Review

                transition,developmentally appropriate healthcare,gh therapy,metabolic syndrome,quality of life

                Comments

                Comment on this article